JPMorgan downgraded Centene (CNC) to Neutral from Overweight with a price target of $48, down from $75, after the company announced it was withdrawing prior FY25 guidance, citing data that demonstrated slower growth and worse morbidity in the broader ACA exchange market as well as a higher-than-anticipated Medicaid trend. The firm’s updated December 2025 price target reflects the estimated ACA headwinds as well as incremental Medicaid pressure, assuming that Centene is able to reprice at least a portion of its book into 2026, the analyst noted.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Centene’s Financial Outlook: Hold Rating Amid Revenue Headwinds and Regulatory Uncertainties
- Centene downgraded to Neutral from Buy at UBS
- Closing Bell Movers: Centene down 24% after pulling 2025 guidance
- Centene down 21% at $44.98 after withdrawing guidance
- Centene withdraws 2025 GAAP, adjusted EPS guidance